Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy

Three-step pretargeting for radioimmunotherapy in BALB/c mice with KHJJ tumors was done with monoclonal antibody (mAb) 2D12.5, which is specific for yttrium-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) but nonspecific for the tumor. Tumor uptake was by passive diffusion of mAb through leaky...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 1994-11, Vol.54 (22), p.5937-5946
Hauptverfasser:	GOODWIN, D. A, MEARES, C. F, WATANABE, N, MCTIGUE, M, CHAOVAPONG, W, RANSONE, C. K, RENN, O, GREINER, D. P, KUKIS, D. L, KRONENBERGER, S. I
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetates - blood Acetates - pharmacokinetics Animals Antibodies, Monoclonal - blood Antibodies, Monoclonal - pharmacokinetics Biological and medical sciences Half-Life Heterocyclic Compounds - blood Heterocyclic Compounds - pharmacokinetics Mammary Neoplasms, Experimental - blood Mammary Neoplasms, Experimental - metabolism Mammary Neoplasms, Experimental - radiotherapy Medical sciences Mice Mice, Inbred BALB C Radiation therapy and radiosensitizing agent Radioimmunotherapy - methods Tissue Distribution Treatment with physical agents Treatment. General aspects Tumors Yttrium Radioisotopes - blood Yttrium Radioisotopes - pharmacokinetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!